{"id":209048,"name":"PTC THERAPEUTICS, INC.","slug":"ptc-therapeutics-inc","state":"NJ","country":"United States of America","description":"Biopharmaceutical therapies for rare pediatric diseases","totalSpending":530000,"filings":13,"yearlySpending":[{"year":2021,"income":180000},{"year":2022,"income":200000},{"year":2023,"income":150000}],"issues":[{"code":"HCR","display":"Health Issues"}],"firms":["THORN RUN PARTNERS"],"lobbyists":["ANDREW ROSENBERG","STUART CHAPMAN","BEAU SCHUYLER"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE","White House Office","Natl Institutes of Health (NIH)"],"sampleDescriptions":["Issues related to the development of therapies for rare diseases.","Issues related to the development of therapies for rare diseases.","Issues related to the development of therapies for rare diseases.","Issues related to the development of therapies for rare diseases.\nFederal funding for Covid-19 therapies. \nIncreased awareness for AADC deficiency.","Issues related to the development of therapies for rare diseases.\nFederal funding for Covid-19 therapies. \nIncreased awareness for AADC deficiency.\nH.R. 742: Supporting the designation of October 23, "]}